Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Johnson & Johnson : J&J Chairman Weldon's Salary Cut To $1 Million After Stepping Down As CEO

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/07/2012 | 11:51pm CEST
   By Peter Loftus 
   Of  
 

Johnson & Johnson (JNJ) Chairman William Weldon's annual base salary was reduced by nearly half to $1 million after he stepped down as chief executive last month, the company said Monday.

Weldon's previous annual base salary was set at $1.97 million for 2012, for his roles as both chairman and CEO, but with the expectation that J&J's board would consider the appropriate compensation for Weldon in his role as chairman only.

The decrease reflects that Weldon is no longer CEO, said spokesman Al Wasilewski.

On April 26, Alex Gorsky succeeded Weldon as CEO. Weldon is continuing as chairman and will remain an employee of the company, J&J said in a quarterly report filed with the Securities and Exchange Commission Monday.

J&J said in a previous SEC filing that in his role as chairman, Weldon will work closely with Gorsky to ensure a seamless leadership transition. During this time, all day-to-day management and operational responsibilities are being transferred to Gorsky.

Weldon will remain an employee but not a member of the J&J executive committee, which is the principal management group responsible for strategic operations and allocations of the resources of the company.

Weldon's main duties as chairman will include working with the board of directors, facilitating communication between the board and management, assisting Gorsky in business planning and strategy, representing the company before governmental and other organizations, and serving as chairman of the board's finance committee.

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; peter.loftus@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
01:47p EARNINGS REVIEW AND FREE RESEARCH RE : Johnson & Johnson’s Adjusted EPS Gr..
01:47p JOHNSON & JOHNSON : Earnings Review and Free Research Report: Johnson & Johnson..
07/19 JOHNSON & JOHNSON : UNFPA Support Training of Midwives As Master Mentors Ends in..
07/19 JOHNSON & JOHNSON : Today's Research Reports on Stocks to Watch: Johnson & Johns..
07/19DJJOHNSON & JOHNSON : J&J Expects Drug Sales to Pick Up -- WSJ
07/19 JOHNSON & JOHNSON : U.S. homebuilder sentiment down in July
07/18 CUTERA : Global Acne Treatment Market 2017 Analysis, by Players - Galderma, Veri..
07/18 JOHNSON & JOHNSON : J&J sees sales growth in near-term; raises 2017 profit forec..
07/18 JOHNSON & JOHNSON : J&J sees sales growth in near-term; raises 2017 profit forec..
07/18 JOHNSON & JOHNSON : ups expectations
More news
News from SeekingAlpha
07:55a Premarket analyst action - healthcare
07/19 How Safe Are The Dividends Of These Stalwarts?
07/19 Johnson & Johnson's Weakness Worries Me
07/19 JOHNSON & JOHNSON : This Market Will Buy Anything
07/19 Immunogen Finally Moving 'FORWARD'?
Financials ($)
Sales 2017 75 820 M
EBIT 2017 22 896 M
Net income 2017 16 676 M
Debt 2017 6 183 M
Yield 2017 2,48%
P/E ratio 2017 22,22
P/E ratio 2018 18,30
EV / Sales 2017 4,89x
EV / Sales 2018 4,52x
Capitalization 364 233 M
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 138 $
Spread / Average Target 2,0%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON17.36%364 233
NOVARTIS8.64%222 570
ROCHE HOLDING LTD.4.56%220 588
PFIZER3.51%200 211
MERCK AND COMPANY6.37%171 276
SANOFI6.94%119 307